EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes

Ditte B Iversen iD, Ann-Cathrine Dalgård Dunvald iD, Daniel M Jespersen, Flemming Nielsen, Kim Brøsen iD, Per Damkier iD, Helen S Hammer, Oliver Pötz iD, Erkka Järvinen iD, Tore B Stage iD

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2959 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Ditte B Iversen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Floxacillin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flucloxacillin is a widely used antibiotic. It is an agonist to the nuclear receptor PXR that regulates the expression of cytochrome P450 (CYP) enzymes. Treatment with flucloxacillin reduces warfarin efficacy and plasma concentrations of tacrolimus, voriconazole, and repaglinide. We conducted a translational study to investigate if flucloxacillin induces CYP enzymes. We also investigated if flucloxacillin induces its own metabolism as an autoinducer. We performed a randomized, unblinded, two‐period, cross‐over, clinical pharmacokinetic cocktail study. Twelve healthy adults completed the study. They ingested 1 g flucloxacillin 3 times daily for 31 days, and we assessed the full pharmacokinetics of the Basel cocktail drugs on days 0, 10, and 28, and plasma concentrations of flucloxacillin on days 0, 9, and 27. The 3D spheroid of primary human hepatocytes (PHHs) were exposed to flucloxacillin (concentration range: 0.15–250 μM) for 96 hours. Induction of mRNA expression, protein abundance, and enzyme activity of CYP enzymes were assessed. Flucloxacillin treatment reduced the metabolic ratio of midazolam (CYP3A4), (geometric mean ratio (GMR) 10 days (95% confidence interval (CI)): 0.75 (0.64–0.89)) and (GMR 28 days (95% CI): 0.72 (0.62–0.85)). Plasma concentrations of flucloxacillin did not change during 27 days of treatment. Flucloxacillin caused concentration‐dependent induction of CYP3A4 and CYP2B6 (mRNA, protein, and activity), CYP2C9 (mRNA and protein), CYP2C19 (mRNA and activity), and CYP2D6 (activity) in 3D spheroid PHH. In conclusion, flucloxacillin is a weak inducer of CYP3A4, which may lead to clinically relevant drug–drug interactions for some narrow therapeutic range drugs that are substrates of CYP3A4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3AFloxacillinHumansAdultCytochrome P-450 Enzyme SystemDrug InteractionsHepatocytesRNA, Messenger

Substanzen

Cytochrome P-450 CYP3AFloxacillinCytochrome P-450 Enzyme SystemRNA, MessengerCYP3A4 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Otterup Pharmacy, Otterup, Denmark.
  • Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Signatope GmbH, Reutlingen, Germany.
  • NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.

ORCID-Profile: Ditte B Iversen, Ann-Cathrine Dalgård Dunvald, Kim Brøsen, Per Damkier, Oliver Pötz, Erkka Järvinen, Tore B Stage

Zitieren

APA

Iversen, D. B., Dunvald, A. D., Jespersen, D. M., Nielsen, F., Brøsen, K., Damkier, P., Hammer, H. S., Pötz, O., Järvinen, E., & Stage, T. B. (2023). Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2959

Vancouver

Iversen DB, Dunvald AD, Jespersen DM, Nielsen F, Brøsen K, Damkier P, et al. Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2959

BibTeX
@article{Iversen2023,
  author = {Iversen, Ditte B and Dunvald, Ann-Cathrine Dalgård and Jespersen, Daniel M and Nielsen, Flemming and Brøsen, Kim and Damkier, Per and Hammer, Helen S and Pötz, Oliver and Järvinen, Erkka and Stage, Tore B},
  title = {Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2959}
}
Kostenlos starten →